NCI advisors approved in concept the Institute’s plan to spend $24 million over five years for research on “patient navigator” programs.
NCI Board of Scientific Advisors also approved a new SBIR grant program for research on circulating cells in cancer detection.
Also in this 8-page issue: David Hohn elected board chairman of the National Comprehensive Cancer Network.
FDA says new tools needed to speed therapeutics development.
Senate confirms McClellan to head CMS. NCI “redeploys” $54.5 million cut from divisions to fund strategic initiatives.
CDC study finds obesity may become leading preventable cause of death; NIH research plan drafted.
Funding opportunities listed.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
